China National Pharmaceutical Group Corporation: Multiple drugs are proposed to be selected for the national centralized procurement of drugs for follow-up procurement.

China National Pharmaceutical Group Corporation (Sinopharm) announced that the company and its subsidiaries will participate in the continuation of the procurement of the 1st-8th batch of drugs in the national centralized drug procurement program. 49 drugs are expected to be selected. The procurement period for the selected drugs is until December 31, 2028, with sales revenue of 2.252 billion yuan in 2024, accounting for 20.59% of the revenue during the same period; sales revenue in the first three quarters of 2025 was 1.602 billion yuan, accounting for 23.15% of the revenue during the same period, with no single product revenue exceeding 5% of the revenue during the same period. The overall price of this procurement is stable, with some prices possibly decreasing. The results of the expected selection are subject to confirmation, and there is uncertainty in the subsequent situation.